Cooley LLP and Matheson LLP advised Horizon, while Sullivan & Cromwell LLP and William Fry LLP advised Amgen. Debevoise & Plimpton LLP advised JP Morgan. Macfarlanes...
Amgen’s Acquisition of Horizon Therapeutics
Poseida Therapeutics’ Collaboration and License Agreement With Roche
Cooley advised Poseida Therapeutics on the deal. Poseida Therapeutics, a clinical-stage biopharmaceutical company, announced its strategic collaboration and license agreement with Roche. The agreement will leverage Poseida’s...
Bristol Myers Squibb’s $4.1 Billion Acquisition of Turning Point Therapeutics
Cooley advised Turning Point Therapeutics, while Kirkland & Ellis advised Bristol Myers Squibb on the deal. Bristol Myers Squibb (NYSE:BMY), a global biopharmaceutical company, announced its...
Immatics’ License Agreement With Bristol Myers Squibb
Cooley LLP advised Immatics on the deal. Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced its license, development...